Loading organizations...
Rivia offers a unified data and AI analytics platform optimizing clinical trials for biotech and pharmaceutical companies. It integrates fragmented trial data, transforming it into actionable insights for enhanced decision-making and accelerated drug development. The platform acts as a next-generation operating system, structuring complex information to unlock potential and streamline research.
Co-founded by CEO Erik Scalfaro and CTO Tiago Kieliger, Rivia originated from Scalfaro's deep experience in the pharmaceutical industry. He identified inefficiencies caused by fragmented clinical trial data. This insight fueled their initiative to build a comprehensive solution addressing these data infrastructure problems, aiming to improve clinical development.
Rivia’s platform primarily supports biotech and pharma organizations, enabling navigation of clinical research complexities. The company's vision involves empowering innovators to bring life-saving drugs to patients faster. Through robust data infrastructure, Rivia aims to foster greater efficiency and breakthroughs across the clinical trial landscape.
Rivia has raised $18.0M across 2 funding rounds.
Rivia has raised $18.0M in total across 2 funding rounds.
Rivia has raised $18.0M across 2 funding rounds. Most recently, it raised $15.0M Series A in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 18, 2026 | $15M Series A | Earlybird | Amino Collective, Defiant, Nina Capital, Speedinvest | Announced |
| Jun 1, 2024 | $3M Seed | — | Cherry Ventures, Nina Capital, Speedinvest, Matthias Hilpert, Amino Collective | Announced |
Rivia is a Zurich, Switzerland-based technology startup that builds a unified data and AI analytics platform for biotech and pharma companies' clinical trials.[1][2][3][4] It serves biotechs and pharma firms by integrating fragmented trial data from various sources into a standardized, real-time database, transforming it into actionable insights for trial planning, execution, safety monitoring, and executive oversight.[1][2][4] The platform solves the core problem of complex, cumbersome clinical trials—often an invisible barrier to therapeutic breakthroughs—by accelerating decision-making, reducing risks and costs, and unlocking hidden potential in trial data to bring therapies to market faster.[1][4]
Rivia demonstrates strong early growth momentum, raising €3M in seed funding led by Speedinvest, with participation from Amino Collective and Nina Capital, to expand engineering, client services, and product development.[3] Trusted by clients like Alentis Therapeutics, it deploys in under 30 days with hourly-updating pipelines and AI agents for real-time dashboards.[4]
Rivia's journey started from firsthand experience in clinical challenges: treating patients, developing patient safety algorithms, and collaborating from a co-founder's apartment, driven by a vision to transform drug development.[1] Founded as a Zurich-based startup, it emerged to tackle the persistent issues of fragmented clinical trial data hindering biotech innovation.[2][3] Key early traction includes securing €3M in seed funding in a round highlighting its AI-driven focus, enabling rapid team growth and product advancement amid a <25 employee base.[3] This bootstrapped-to-funded evolution positions Rivia as a specialist in biopharma infrastructure, headquartered at Technoparkstrasse in Zürich.[3]
(Note: A separate entity at riviaco.com focuses on SME healthcare access in Ghana via clinics and access cards, but query context aligns with the biotech Rivia at rivia.com/rivia.ch.[5])
Rivia rides the wave of AI-driven drug development, where fragmented clinical trial data—spanning vendors, formats, and siloed teams—delays therapies amid rising biopharma R&D costs exceeding $2B per drug.[1][2] Timing is ideal as AI adoption surges in biotech post-2023 funding winters, with platforms like Rivia enabling real-time analytics to cut trial timelines by months and boost success rates.[3][4] Market forces favoring it include explosive growth in biotech trials (over 5,000 active globally), regulatory pushes for data transparency (e.g., FDA real-world evidence), and investor appetite for AI-biotech infrastructure, as seen in its €3M seed.[3] Rivia influences the ecosystem by democratizing advanced analytics for smaller biotechs, fostering innovation that accelerates patient access to new treatments worldwide.[1]
Rivia is poised to scale as the go-to unified platform for clinical trial data, leveraging its seed funding for engineering hires and product enhancements to capture share in a $50B+ clinical ops market.[3] Trends like multimodal AI agents, federated learning for privacy, and multimodal trial data (genomics + imaging) will shape its path, potentially expanding to predictive modeling for trial design.[2][4] Its influence may evolve from early-stage integrator to ecosystem leader, powering "therapeutic innovation" for hundreds of biotechs—unlocking hidden trial potential to deliver breakthroughs faster, just as its apartment origins envisioned.[1]
Rivia has raised $18.0M in total across 2 funding rounds.
Rivia's investors include Earlybird, Amino Collective, Defiant, Nina Capital, Speedinvest, Cherry Ventures, Matthias Hilpert.
